SCHEMBL3007499

SCHEMBL3007499

CCc1ccc(-c2csc(N3CCC(S(=O)(=O)c4ccc(OC)cc4OC)CC3)n2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.51
RAB9A P51151 5/20 0.51
MAPT P10636 13/20 0.49
LMNA P02545 8/20 0.49
TDP1 Q9NUW8 2/20 0.49
NPC1 O15118 3/20 0.48
ALDH1A1 P00352 7/20 0.46
POLB P06746 2/20 0.45
MAPK1 P28482 6/20 0.43
USP2 O75604 3/20 0.43
TP53 P04637 2/20 0.43
HTT P42858 2/20 0.43
ALOX15 P16050 1/20 0.43
HSD17B10 Q99714 3/20 0.42
HPGD P15428 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
RECQL P46063 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007022 0.93 RAB9A (0.49) SMN1; SMN2RAB9AMAPTLMNATDP1
SCHEMBL3014151 0.93 RAB9A (0.53) SMN1; SMN2RAB9AMAPTLMNATDP1
SCHEMBL3007225 0.93 SMN1; SMN2 (0.58) SMN1; SMN2RAB9AMAPTLMNATDP1
SCHEMBL3002158 0.91 SMN1; SMN2 (0.51) SMN1; SMN2RAB9AMAPTLMNATDP1
SCHEMBL3016315 0.90 SMN1; SMN2 (0.53) SMN1; SMN2RAB9AMAPTLMNATDP1
SCHEMBL3008140 0.89 RAB9A (0.52) SMN1; SMN2RAB9AMAPTLMNATDP1
SCHEMBL3017084 0.89 MAPT (0.57) SMN1; SMN2RAB9AMAPTLMNATDP1
SCHEMBL3014374 0.88 SMN1; SMN2 (0.57) SMN1; SMN2RAB9AMAPTLMNATDP1
SCHEMBL3014942 0.88 SMN1; SMN2 (0.50) SMN1; SMN2RAB9AMAPTLMNATDP1
SCHEMBL3014322 0.88 MAPT (0.38) SMN1; SMN2RAB9AMAPTLMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.